125 related articles for article (PubMed ID: 27765910)
1. Suppression of gain-of-function mutant p53 with metabolic inhibitors reduces tumor growth in vivo.
Jung CL; Mun H; Jo SY; Oh JH; Lee C; Choi EK; Jang SJ; Suh YA
Oncotarget; 2016 Nov; 7(47):77664-77682. PubMed ID: 27765910
[TBL] [Abstract][Full Text] [Related]
2. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
Di Fiore R; Marcatti M; Drago-Ferrante R; D'Anneo A; Giuliano M; Carlisi D; De Blasio A; Querques F; Pastore L; Tesoriere G; Vento R
Bone; 2014 Mar; 60():198-212. PubMed ID: 24373920
[TBL] [Abstract][Full Text] [Related]
4. Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.
Vaughan CA; Singh S; Grossman SR; Windle B; Deb SP; Deb S
Mol Oncol; 2017 Jun; 11(6):696-711. PubMed ID: 28423230
[TBL] [Abstract][Full Text] [Related]
5. Andrographolide induces degradation of mutant p53 via activation of Hsp70.
Sato H; Hiraki M; Namba T; Egawa N; Baba K; Tanaka T; Noshiro H
Int J Oncol; 2018 Aug; 53(2):761-770. PubMed ID: 29845212
[TBL] [Abstract][Full Text] [Related]
6. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of the intercellular adhesion molecule-2 gene as a novel p53 target.
Sasaki Y; Tamura M; Takeda K; Ogi K; Nakagaki T; Koyama R; Idogawa M; Hiratsuka H; Tokino T
Oncotarget; 2016 Sep; 7(38):61426-61437. PubMed ID: 27556181
[TBL] [Abstract][Full Text] [Related]
8. Death-associated protein kinase 1 promotes growth of p53-mutant cancers.
Zhao J; Zhao D; Poage GM; Mazumdar A; Zhang Y; Hill JL; Hartman ZC; Savage MI; Mills GB; Brown PH
J Clin Invest; 2015 Jul; 125(7):2707-20. PubMed ID: 26075823
[TBL] [Abstract][Full Text] [Related]
9. Targeted p53 activation by saRNA suppresses human bladder cancer cells growth and metastasis.
Wang C; Ge Q; Zhang Q; Chen Z; Hu J; Li F; Ye Z
J Exp Clin Cancer Res; 2016 Mar; 35():53. PubMed ID: 27012825
[TBL] [Abstract][Full Text] [Related]
10. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy.
Bossi G; Marampon F; Maor-Aloni R; Zani B; Rotter V; Oren M; Strano S; Blandino G; Sacchi A
Cell Cycle; 2008 Jun; 7(12):1870-9. PubMed ID: 18594199
[TBL] [Abstract][Full Text] [Related]
11. CP-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo.
He X; Kong X; Yan J; Yan J; Zhang Y; Wu Q; Chang Y; Shang H; Dou Q; Song Y; Liu F
Tumour Biol; 2015 Mar; 36(3):1437-44. PubMed ID: 25663456
[TBL] [Abstract][Full Text] [Related]
12. p53 functional deficiency in human colon cancer cells promotes fibroblast-mediated angiogenesis and tumor growth.
Hayashi Y; Tsujii M; Kodama T; Akasaka T; Kondo J; Hikita H; Inoue T; Tsujii Y; Maekawa A; Yoshii S; Shinzaki S; Watabe K; Tomita Y; Inoue M; Tatsumi T; Iijima H; Takehara T
Carcinogenesis; 2016 Oct; 37(10):972-984. PubMed ID: 27520561
[TBL] [Abstract][Full Text] [Related]
13. Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth.
Fei P; Wang W; Kim SH; Wang S; Burns TF; Sax JK; Buzzai M; Dicker DT; McKenna WG; Bernhard EJ; El-Deiry WS
Cancer Cell; 2004 Dec; 6(6):597-609. PubMed ID: 15607964
[TBL] [Abstract][Full Text] [Related]
14. Repurposing Metabolic Inhibitors in the Treatment of Colon Adenocarcinoma Patient-Derived Models.
Lee B; Lee C; Moon HM; Jo SY; Jang SJ; Suh YA
Cells; 2023 Dec; 12(24):. PubMed ID: 38132178
[TBL] [Abstract][Full Text] [Related]
15. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
17. Gain-of-function of mutant p53: mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells.
Ali A; Shah AS; Ahmad A
Cancer Lett; 2014 Nov; 354(1):87-96. PubMed ID: 25111898
[TBL] [Abstract][Full Text] [Related]
18. Addition of 2-deoxyglucose enhances growth inhibition but reverses acidification in colon cancer cells treated with phenformin.
Lea MA; Chacko J; Bolikal S; Hong JY; Chung R; Ortega A; desbordes C
Anticancer Res; 2011 Feb; 31(2):421-6. PubMed ID: 21378320
[TBL] [Abstract][Full Text] [Related]
19. Induction of genetic instability by gain-of-function p53 cancer mutants.
Xu Y
Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
[TBL] [Abstract][Full Text] [Related]
20. Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression.
Yue X; Zhang C; Zhao Y; Liu J; Lin AW; Tan VM; Drake JM; Liu L; Boateng MN; Li J; Feng Z; Hu W
Genes Dev; 2017 Aug; 31(16):1641-1654. PubMed ID: 28947497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
